Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-10-24

FDA Approved: ZIPRASIDONE HYDROCHLORIDE — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

The FDA approved a supplemental application for ziprasidone hydrochloride from BluePoint Laboratories, granting ANDA-based approval of a generic form of ziprasi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZIPRASIDONE HYDROCHLORIDE (Ziprasidone hydrochloride)

Snippet

SUPPL AP for ZIPRASIDONE HYDROCHLORIDE (ZIPRASIDONE HYDROCHLORIDE)